A supplement formulation including a combination of vitamins, minerals, amino acids, and stimulants, and a delivery method and device for said supplement formulation. Caffeine is present in the supplement formulation in an amount of about 40-60 mg/ml, of which about 15-30 mg/ml is caffeine from coffee beans and about 15-30 mg/ml is caffeine from green tea extract. About 5-20 mg/ml caffeine from guarana seed extract may also be present. Such a delivery device provides the supplement to a mouth/throat area of a user where it is readily absorbed in the mouth/throat area of the user or ingested by the user.

The present invention provides a therapeutic composition comprising a synergistic combination of caffeine, Ginkgo biloba, and β-phenylethylamine (PEA) or its salt. The invention is also directed to oral dosage forms containing said composition, and to a method of treatment of a psychological, psychiatric, behavioral and/or neurodevelopmental disorder comprising the administration of said compositions and dosage forms to a patient in need thereof.

The present invention provides a therapeutic composition comprising a synergistic combination of caffeine, Ginkgo biloba, and β-phenylethylamine (PEA) or its salt. The invention is also directed to oral dosage forms containing said composition, and to a method of treatment of a psychological, psychiatric, behavioral and/or neurodevelopmental disorder comprising the administration of said compositions and dosage forms to a patient in need thereof.

The present invention provides a therapeutic composition comprising a synergistic combination of caffeine, Ginkgo biloba, and β-phenylethylamine (PEA) or its salt. The invention is also directed to oral dosage forms containing said composition, and to a method of treatment of a psychological, psychiatric, behavioral and/or neurodevelopmental disorder comprising the administration of said compositions and dosage forms to a patient in need thereof.

A pharmaceutical composition for treating one or more symptoms of insomnia is disclosed herein. The pharmaceutical composition includes an amount of cannabidiol (CBD) and an amount of delta-9-tetrahydrocannabinol (THC), wherein the amount of CBD and the amount of THC are effective in treating insomnia. The pharmaceutical composition may include an amount of a selected herb and an amount of another cannabinoid. A pharmaceutical composition for treating one or more symptoms of chronic and acute pain using an amount of CBD and/or THC is also disclosed herein. The pharmaceutical composition may include an amount of another cannabinoid. A pharmaceutical composition for treating one or more symptoms of skin diseases and conditions using CBD and/or THC is also disclosed herein. The pharmaceutical composition may include an amount of another cannabinoid, an essential oil, a permeation enhancer, and/or an anti-bacterial/anti-viral agent.

A pharmaceutical composition for treating one or more symptoms of insomnia is disclosed herein. The pharmaceutical composition includes an amount of cannabidiol (CBD) and an amount of delta-9-tetrahydrocannabinol (THC), wherein the amount of CBD and the amount of THC are effective in treating insomnia. The pharmaceutical composition may include an amount of a selected herb and an amount of another cannabinoid. A pharmaceutical composition for treating one or more symptoms of chronic and acute pain using an amount of CBD and/or THC is also disclosed herein. The pharmaceutical composition may include an amount of another cannabinoid. A pharmaceutical composition for treating one or more symptoms of skin diseases and conditions using CBD and/or THC is also disclosed herein. The pharmaceutical composition may include an amount of another cannabinoid, an essential oil, a permeation enhancer, and/or an anti-bacterial/anti-viral agent.

The present invention relates to a field of treatment and prevention of overweight and obesity. In particular the present invention is directed to an oral composition comprising (beta)-escin (beta-escin) for use in prevention of extracellular to intracellular water ratio (ECW/ICW) increase in weight loss interventions in treatment of overweight and obesity. Therefore, the composition of the invention has a beneficial effect on fluid distribution during weight loss. The composition of the invention not only improves ECW/ICW ratio but also induces an anorectic effect and results in appetite suppression. Therefore, it is useful alone as overweight and obesity intervention.

The present invention relates to a field of treatment and prevention of overweight and obesity. In particular the present invention is directed to an oral composition comprising (beta)-escin (beta-escin) for use in prevention of extracellular to intracellular water ratio (ECW/ICW) increase in weight loss interventions in treatment of overweight and obesity. Therefore, the composition of the invention has a beneficial effect on fluid distribution during weight loss. The composition of the invention not only improves ECW/ICW ratio but also induces an anorectic effect and results in appetite suppression. Therefore, it is useful alone as overweight and obesity intervention.

At least one kind of herbal medicine selected from the group consisting of: Component (1): Longan aril, common fenugreek seed, Lycium fruit, songaria cynomorium herb, black sesame, Dipsacus japonicus root, Drynaria herb, flatstem milkvetch seed, black bean, stink-bug, sea horse and donkey glue. Component (2): Ligustrum fruit, oyster shell, yerbadetajo herb, mulberry fruit, cassia seed, mentha herb, mulberry leaf, gardenia fruit, green tea leaf, tangle weed, Chrysanthemum indicum L., Oldenlandia herbacea, plantago seed, plantago herb, wheat seed, feather cockscomb seed, chrysanthemum flower, dandelion herb, Isatis tinctoria L., barbated skullcup herb, snowbellleaf tickclover herb, turmeric, garden burnet root, and Crocus sativus. Component (3): Curcuma rhizome, Suberect spatholobus stem, wild turmeric, Sparganium rhizome, Luffa aegyptica Mill., Carthamus tinctorius, Artemisia anomala, Hairyveine agrimonia herb, Fortune windmillpalm petiole, Dalbergia odorifera, dragon's blood, leech, Panax notoginseng root, Aizoon stonecrop herb, Ophicalcitum, and lotus root node.

At least one kind of herbal medicine selected from the group consisting of: Component (1): Longan aril, common fenugreek seed, Lycium fruit, songaria cynomorium herb, black sesame, Dipsacus japonicus root, Drynaria herb, flatstem milkvetch seed, black bean, stink-bug, sea horse and donkey glue. Component (2): Ligustrum fruit, oyster shell, yerbadetajo herb, mulberry fruit, cassia seed, mentha herb, mulberry leaf, gardenia fruit, green tea leaf, tangle weed, Chrysanthemum indicum L., Oldenlandia herbacea, plantago seed, plantago herb, wheat seed, feather cockscomb seed, chrysanthemum flower, dandelion herb, Isatis tinctoria L., barbated skullcup herb, snowbellleaf tickclover herb, turmeric, garden burnet root, and Crocus sativus. Component (3): Curcuma rhizome, Suberect spatholobus stem, wild turmeric, Sparganium rhizome, Luffa aegyptica Mill., Carthamus tinctorius, Artemisia anomala, Hairyveine agrimonia herb, Fortune windmillpalm petiole, Dalbergia odorifera, dragon's blood, leech, Panax notoginseng root, Aizoon stonecrop herb, Ophicalcitum, and lotus root node.